Cardiovascular Research Technologies (CRT) 2013


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Cardiovascular Research Technologies (CRT) 2013

  2. 2. Dear Colleagues, Among its many highlights, CRT 2013 features over meeting, and will feature an in-depth review of the On behalf of all of the course co-directors, I 300 world-renowned faculty, live cases from seven diagnostic and therapeutic options for the treatment am thrilled to present Cardiovascular Research sites across the globe, simulators and hands-on of valve and structural heart disease. Technologies (CRT) 2013. Building on many years workshops. All of this is presented in an intimate of success, CRT 2013 is our most cutting-edge and I look forward to welcoming you to Washington, DC atmosphere to allow frequent interaction with comprehensive meeting to date. The course features and to CRT 2013. featured experts. concurrent meetings in six subject areas—Valve & Structural Heart, Coronary, Endovascular, Science, New to CRT 2013 is an investigation of the role Warm Regards, Technology and Nurse & Tech—all in CRT’s signature of imaging of atherosclerotic plaque, a review of boutique setting. This robust program allows us to the status of HDL therapy and an introduction to iMPACT YOUR PRACTICE with educational content renal denervation for the treatment of resistant that can be directly applied to your clinical and hypertension. The four-day Valve & Structural Heart Ron Waksman, MD academic practice. track continues to be the leading East Coast valve Course Chairman, CRT 2013 Ron Waksman, MD Course ChairmanSATURDAY, FEBRUARY 23 SUNDAY, FEBRUARY 24 MONDAY, FEBRUARY 25 TUESDAY, FEBRUARY 26 On-Site Registration Opens Breakfast Symposia Breakfast Symposia Breakfast Symposia Valve Evening Symposium ACS & AMI Management Abstract Café Complex Coronary Interventions II CTO Forum Complex Coronary Interventions I Valve & Structural Heart Revolution IV Valve & Structural Heart Revolution I Valve & Structural Heart Revolution II & III Renal Denervation for Resistant Hypertension Primer for Endovascular Interventions Peripheral Arterial Disease & Cardiovascular Innovations Critical Limb Ischemia Cardiovascular Professionals’ Symposium FDA Town Hall for Nurses & Techs DES Bioabsorbable and DCB Technologies Women & Heart Disease Luncheon Symposium Atherosclerosis, Plaque Imaging and Lipid Therapy Exhibitor Reception Evening Dinner Symposia The Essentials of Clinical Research Evening Dinner Symposia
  3. 3. COURSE INFORMATIONCOURSE DESCRIPTION LEARNING OBJECTIVES TARGET AUDIENCE DISCLOSURE OF FINANCIAL RELATIONSHIPSCardiovascular Research Technologies (CRT) • Compare the results from important This educational program is designed WITH ANY COMMERCIAL INTEREST2013 will be the most comprehensive clinical trials and evidence-based for interventional cardiologists, clinical As a sponsor accredited by the ACCME, it isand cutting-edge CRT conference to date. medicine to guide management of cardiologists, cardiac surgeons, fellows, the policy of MedStar Washington HospitalThrough six subject areas – Coronary, Valve patients with atherosclerosis and emergency medicine specialists, primary Center to require that everyone who is& Structural Heart, Endovascular, Science, structural heart disease care physicians, basic scientists, in a position to control the content of anTechnology and Nurse & Tech – CRT 2013’s radiologists, interventional radiologists, educational activity disclose all relevant • Incorporate new interventional14 concurrent meetings are designed to nurses, technologists, industry professionals financial relationships with any commercial technologies, drugs and proceduresimpact practice with focused sessions that and other health care professionals who interest prior to the educational activity. into the care of patients with complexdiscuss new trial data, explore evidence- want to enhance their knowledge of complex coronary and endovascular disease The ACCME considers relationships ofbased research and demonstrate cutting-edge coronary interventions and the treatment of the person involved in the CME activity totechniques that can be directly applied to • Integrate advances in diagnostic patients with cardiovascular disease. include financial relationships of a spouse orthe learners’ clinical and academic practice. evaluation and therapeutics to treat partner. Faculty and planners who refuse toThis four-day conference will feature over 300 patients with carotid and peripheral CME ACCREDITATION disclose relevant financial relationships willworld-renowned faculty and live cases from arterial disease MedStar Washington Hospital Center is be disqualified from participating in the CMEseven sites across the globe. accredited by the Accreditation Council for • Assess percutaneous devices from activity. For an individual with no relevantThe meetings as well as some of the breakfast device concept to preclinical trial to Continuing Medical Education to provide financial relationship(s), the participantsand evening symposia in the Coronary, clinical investigation to regulatory continuing medical education for physicians. must be informed that no conflicts of interestEndovascular, Science, Nurse & Tech and approval and clinical application for the or financial relationship(s) of the Valve & Structural Heart tracks treatment of structural heart and valve CREDIT DESIGNATIONare eligible for CME credit. The meetings disease MedStar Washington Hospital Center SPECIAL ASSISTANCEin the Technology track as well as Valve & designates this live activity for a maximum MedStar Washington Hospital Center wishesStructural Heart IV and the clinical simulation • Describe appropriate pharmacologic of 32 AMA PRA Category 1 CreditsTM. to ensure that no individual with a disabilitystations are not eligible for CME credit. management in the care of patients Physicians should claim only the credit is excluded, denied services, segregated undergoing diagnostic arteriography and commensurate with the extent of their or otherwise treated differently from other interventional therapies before, during, participation in the activity. individuals because of the absence of and after cardiac catheterization auxiliary aids or services identified in the • Evaluate and develop an effective Americans with Disabilities Act. Please clinical research program contact 202-877-8206 to notify us of your needs. FOR THE MOST UPDATED PROGRAM INFORMATION PLEASE VISIT CRTMEETING.ORG
  4. 4. CORONARYACS & AMI Management CTO Forum Complex Coronary InterventionsSunday, February 24 Sunday, February 24 Monday, February 25 & Tuesday, February 26COURSE DIRECTORS COURSE DIRECTORS COURSE DIRECTORSC. Michael Gibson, MD Richard R. Heuser, MD Maurice Buchbinder, MD Lowell F. Satler, MDNeal S. Kleiman, MD Craig A. Thompson, MD Kenneth M. Kent, MD Ron Waksman, MDHIGHLIGHTS HIGHLIGHTS HIGHLIGHTS• New Antiplatelet Agents: How to Optimize Therapy for • CTO Recanalization: For Beginners through Masters • Live Case Demonstrations from 7 International Sites Patients with ACS and AMI • New Wire and Support Catheter Technologies • Appropriate Use Criteria for PCI• How to Select the Appropriate Antiplatelet Agent • Antegrade and Retrograde Approach: Step-by-Step • Clinical Trials that Will Impact Your Practice• Antiplatelet Therapy Responsiveness and Genomics Tutorial • Unprotected Left Main: Patient Selection and Technique• Optimal Duration of DAPT • CTO Complications • Thrombus and No-Reflow Management• How to Minimize Bleeding Complications • Imaging to Guide CTO Recanalizations • Bifurcation: Technical Strategies• Anticoagulation Protocols for NSTEMI/STEMI • Live Case Demonstrations from the Experts in Japan • How to Manage Complications in PCI• Strategies to Shorten Door-to-Balloon Time • Patient and Lesion Selection • Transradial Access: Tips and Tricks• Hemodynamic Support Devices for Complex PCI and • Strategies to Increase Your Success Rate • When to Use FFR and when to Use IVUS Cardiogenic Shock • New Devices and Tools for CTO Recanalization • How to Perform a Transseptal• How to Manage the “No-Reflow” Phenomenon • Challenging Case Reviews • Use of Atheroablative Devices in 2013• How to Shorten Door-to-Balloon Time • Strategies to Minimize Radiation and Contrast • Management of Multivessel Disease• OCT and FFR Use in STEMI Patients • Radial Access for CTO • Therapeutic Options for Saphenous Vein Grafts • Peripheral CTO
  5. 5. VALVE & STRUCTURAL HEARTValve & Structural Heart RevolutionSaturday, February 23 – Tuesday, February 26COURSE DIRECTORSNiv Ad, MD Michael J. Mack, MD Paul J. Corso, MD Augusto D. Pichard, MD Eberhard Grube, MD Ron Waksman, MDHIGHLIGHTS AORTIC VALVE MITRAL VALVE• Live Cases and Taped Case Sessions • How to Set Up a Successful TAVR Program in Your • Understanding Mitral Valve Disease Institution: Readiness, Planning and Training• Review of the Latest Clinical Data from the Valve Studies • Percutaneous Mitral Valve Repair Technology: Update, • TAVR Technology: Balloon-Expandable and Techniques, Patient Selection and Therapeutic Options• Practical Tutorial: How to Start a Valve and Structural Self-Expandable Technology Update Heart Program • Understanding Treatment Options for Mitral • TAVR: Step-by-Step Guidance Regurgitation• Hands-On Simulators for Valve and Structural Heart Devices • TAVR Technology: Balloon-Expandable and • Percutaneous Mitral Valve Replacement Self-Expandable Technology Update• Review of the Latest Clinical Data on Valve & Structural Heart • TAVR: Review of the Latest Clinical Data STRUCTURAL HEART• Tutorial on Interventional Techniques for • Transapical vs. Transfemoral • Left Atrial Appendage Closure: Technology Update and Cardiothoracic Surgeons Review of the Data • Transaortic and Subclavian Access for TAVR• Review of Challenging Cases and Complications • PFO Closure in 2013: Indications and Device Selection • Imaging for TAVR• Parade of New Valve and Structural Heart Technology • VSD Closure • Transcatheter Valve-in-Valve• Regulatory and Health Care Issues Related to Valve and • How to Minimize Aortic Regurgitation • Valvular Leak Closure: Technology and Technique Structural Heart Disease • TAVR for Lower Risk Patients• Vascular Access and Closure • Embolic Protection Devices to Minimize Stroke• Valve Revolution Evening Symposium FOR THE MOST UPDATED PROGRAM INFORMATION PLEASE VISIT CRTMEETING.ORG
  6. 6. ENDOVASCULARENDOVASCULAR Primer for Endovascular Interventions Sunday, February 24 Peripheral Arterial Disease & Critical Limb Ischemia Monday, February 25 COURSE DIRECTORS COURSE DIRECTORS J. Michael Bacharach, MD, MPH J. Michael Bacharach, MD, MPH Nelson L. Bernardo, MD Nelson L. Bernardo, MD Mark H. Wholey, MD Mark H. Wholey, MD HIGHLIGHTS HIGHLIGHTS • Techniques and Imaging Guidance for Femoral Artery Access • Live Case Demonstrations • Approaches to Access of the Radial, Brachial and Popliteal Arteries • LINC at CRT • Hemostasis with Suture-Mediated Vascular Closure Devices and Vascular Closure Plugs • Interesting and Complicated Case Review • Endovascular Approach to Aorto-Iliac Occlusive Disease • Complications and Bailout Sessions • Retrograde Pedal Artery Access Techniques • Chronic Limb Ischemia: New Tools and Techniques • Intervention of the Subclavian, Renal and Mesenteric Arteries • New Atherectomy Devices for SFA and Below-the-Knee • Tutorial on the Use of Various Atherectomy Devices • Laser Angioplasty for Limb Salvage • Surgical and Endovascular Approach to Acute Limb Ischemia • OCT-Guided Atherectomy for SFA Reacanalization • Carotid Artery Revascularization with Surgery or Stenting • CTO for SFA and Below-the-Knee • Catheter-Based Treatment of DVT • Drug-Coated Balloon and Drug-Eluting Stent Technologies for • Choosing and Implanting an IVC Filter Endovascular Therapy of PAD • Treating Pulmonary Embolism in the Cath Lab • Management of Chronic Limb Ischemia and Infrapopliteal Disease • EVAR Planning and Step-by-Step Device Implantation • Strategies to Minimize Amputations • Dealing with Complications of the Various Arterial Beds • Hands-On Simulation Stations
  7. 7. TECHNOLOGYDES Bioabsorbable and DCB Renal Denervation for Resistant Cardiovascular Innovations FDA Town HallTechnologies Hypertension Tuesday, February 26 Tuesday, February 26Monday, February 25 Tuesday, February 26 COURSE DIRECTORS COURSE DIRECTORS Steven R. Bailey, MD Andrew Farb, MD COURSE DIRECTORS COURSE DIRECTORS Ran Kornowski, MD John S. Sapirstein, MDAlexandre Abizaid, MD, PhD Horst Sievert, MD Ron Waksman, MDAdnan Kastrati, MD Ron Waksman, MD Bram D. Zuckerman, MDLaura Mauri, MDHIGHLIGHTS HIGHLIGHTS HIGHLIGHTS HIGHLIGHTS• Third Generation DES: Update on • Pathophysiology and Mechanism for • Cardiovascular Innovations Competition • Valve and Regulatory Issues Technology and Clinical Outcomes Sympathetic Renal Denervation • Robotic Angioplasty in the Cath Lab • Pathways for Approval of Bioabsorbable• Review of the Latest Data on DES with • Patient Selection and Eligibility Technologies • Telemedicine Devices to Detect Durable Polymers • How to Perform the Procedure: Case Coronary Events • Drug-Coated Balloons• New DES Technology with Presentations • Embolic Protection Devices • TAVR Trial Design for Intermediate Risk Biodegradable Polymers • RF Technology Patient with AS • Artificial Heart• DES with Polymer-Free Technology • Ultrasound Technology • Renal Denervation Regulatory Aspects • New Percutaneous Valves and Valve• The Biodegradable Stent Symposium • Local Drug Delivery Repair Devices • Trial Design for Mitral Valve Repair• The Drug-Coated Balloon Symposium • Brachytherapy • VSD, ASD, PFO & LAA Closures • Reviving First-in-Man Studies in the US• Strategies to Minimize Stent Thrombosis • Clinical Trial Updates • Percutaneous Therapies for the • How Will Health Care Reform Impact• Industry Update on Technology Treatment of Erectile Dysfunction Innovation in Cardiovascular Medicine? • Potential Future Indications: Diabetes, Heart Failure, Sleep Apnea, Renal • ICI @ CRT: A Parade of Novel • Update on 510(k) Artery Stenosis Technologies from Israel • Pathways to Shorten PMA Approval Time FOR THE MOST UPDATED PROGRAM INFORMATION PLEASE VISIT CRTMEETING.ORG
  8. 8. SCIENCE NURSE & TECHAtherosclerosis, Plaque Imaging The Essentials of Clinical Research Cardiovascular Professionals’ Symposium for Nurses & Techsand Lipid Therapy Monday, February 25 Sunday, February 24Monday, February 25 COURSE DIRECTORSCOURSE DIRECTORS COURSE DIRECTORS Regina Deible, RN, BSN H. Bryan Brewer, Jr., MD Ajay J. Kirtane, MD Marsha Holton, CCRN, RCIS Renu Virmani, MD Alexandra J. Lansky, MD Julie Logan, RN Robert L. Wilensky, MD Steven Simms, BSN, RN HIGHLIGHTS HIGHLIGHTS HIGHLIGHTS• New Mechanisms • How to Develop a Successful Research • Successful Sedation: Know Your Options Program• Non-Invasive Plaque Imaging • Closure Devices for Nurse and Tech Management• OCT • Clinical Research: The Basic Roadmap and Essentials of Study Design • Access Management: Radial vs. Femoral• IVUS/VH • To Stent or Not to Stent: Health Care Appropriate Decisions • Investigator-Sponsored Trials• LIPISCAN • A Balanced Approach to PCI: Treating Ischemia and Eliminating Bleeding • How to Survive an FDA Audit• CT/FFR • How to Write a Successful Grant • Renal Denervation: Hope or Hype?• IVUS/FFR Correlation • How to Improve Enrollment in Clinical • Cath Lab Credentials: Who Runs the Table in 2013?• Lipid Content and Vulnerable Plaque Trials • Cath Lab Cross Coverage• CETP Inhibitors: Update on Clinical Trials • Interventional Cardiovascular Research: • Women & Heart Disease Luncheon Symposium• New Insights into HDL Therapy, Experimental Pathways and Regulatory Dysfunctional HDL and Cardiovascular Requirements for Device Approval • Impact of Health Care Reform on Cath Lab Efficiency Genetics • Prepare Your Lab for a Percutaneous Valve Program • Basic Statistics for the Trialist• Review of Clinical Trials • Conquering the Complex PCI & STEMI• Emerging Directions for Diagnosis and • Hot Trends in the Lab Treatment of Dyslipidemia
  9. 9. CALL FOR SUBMISSIONSCALL FOR ABSTRACTS CALL FOR CARDIOVASCULAR INNOVATIONS CALL FOR iMPACT TRIALS CALL FOR YOUNG LEADERSThe CRT 2013 Abstract Committee invites you Do you have a great idea for a new innovative Submit your iMPACT Trials for presentation The Young Leadership Recognitionto submit abstracts of original investigations product? We are actively searching for at CRT 2013. iMPACT Trials are Program is designed to feature current andfor consideration at CRT 2013. Abstracts the latest cardiovascular innovations, innovative reports which provide the latest future clinical and academic excellenceshould constitute original research, (clinical inventions and therapies to be presented breakthroughs in clinical science. The in physicians practicing interventionalstudies, basic investigation and animal and discussed at CRT 2013. Please submit studies selected are expected to highlight cardiology and endovascular medicine.studies are equally encouraged) in the field of information on devices, software, imaging new improvements for quality of patient A special symposium including currentcardiovascular medicine and intervention. The equipment, percutaneous valve therapies, care and significantly “iMPACT” the field leaders in the field from academia,top abstracts will be presented orally at CRT stent technologies, structural heart devices, of interventional cardiology. In addition to industry and the FDA will be held at CRT2013 and the presenting authors will be listed endovascular intervention technologies. the exposure among colleagues and in the 2013 for the selected Young Leadershipas CRT 2013 Associate Faculty. Submit your innovations to be considered for press, selected iMPACT Trial presenters will Recognition Program participants. the Best Innovation Award. become CRT 2013 Associate Faculty.CALL FOR INTERESTING CASES All Cardiovascular Innovations submissionsCRT 2013 invites you to showcase will be reviewed and graded by the CRTinteresting and challenging cases for CALL FOR SUBMISSION DEADLINE Faculty Review Panel; selected submissionseducational purposes. We are particularly will be presented at the Cardiovascular Abstracts November 16, 2012interested in cases in the following Innovations session on Tuesday, February 26,categories: 2013. Cardiovascular Innovations November 16, 2012 • Coronary Intervention Interesting Cases November 16, 2012 • Endovascular Intervention Accepted CRT 2013 abstracts • Valve & Structural Heart Disease Young Leaders November 16, 2012 meeting the eligibility • Renal Denervation requirements will be published iMPACT Trials December 20, 2012 • Complications in the Journal of the American College of Cardiology (JACC) Interventions.HOW TO BECOME CRT 2013 ASSOCIATE FACULTYCRT 2013 is pleased to invite you to become an Associate Faculty member. You may be eligible for the title of Associate Faculty in one of the following ways:• Your abstract is selected to be presented orally.• Your Interesting Case submission is selected to be presented during an Interesting Case Session at CRT 2013.• Your iMPACT Trial is selected to be presented at CRT 2013. FOR THE MOST UPDATED PROGRAM INFORMATION PLEASE VISIT CRTMEETING.ORG
  10. 10. LIVE CASES & SPECIAL EVENTSLIVE CASE DEMONSTRATION SITES EXHIBITOR RECEPTION DISPARITIES IN INTERVENTIONAL CARDIOLOGY Please join us Sunday, February 24, 2013, Disease and Lesion SpecificBrussels University Hospital from 5:30 – 7:00 PM for an assortment of prevention, detection & treatment Monday, February 25, 2013 hors d’oeuvres, festive food stations, drinksBrussels, Belgium Luncheon Symposium and music while interacting with exhibitors.Kusatsu Heart Center Sunday, February 24, 2013 EXHIBIT HALL HOURS 12 – 2 PMKusatsu, Japan Sunday, February 24 11 AM – 7 PMMedStar Washington Hospital Center Monday, February 25 8 AM – 5 PM Join us for the 4th Annual Women &Washington, DC Tuesday, February 26 9 AM – 2 PM Heart Disease Symposium at CRT 2013. Developed in collaboration with the This special lunch session discusses the Association of Black Cardiologists (ABC),Morristown Medical Center EXHIBITS disparities in detecting and treating heart this special luncheon event will examine Is your company interested in exhibiting disease in women. With its outstanding the range of disparities in treating patients,Morristown, New Jersey at CRT 2013? Please visit faculty and candid panel discussions, including gender, racial and economic, and and click “Exhibitors” to view the Exhibitor this session has become a “must-attend” will discuss ways to address them.Mount Sinai Medical Center Prospectus for exhibiting and sponsorship program at CRT.New York, New York information. Please complete the online registration form to reserve your space today!Park HospitalLeipzig, Germany ABSTRACT CAFÉ AN EVENING WITH RUDY GIULIANI CRT 2013 will be hosting the Abstract Café MONDAY, FEBRUARY 25, 2013 | 8:00 PMSan Raffaele Hospital featuring accepted abstracts on Monday, Rudolph W. Giuliani, 107th Mayor of New York City (1993 – 2007),Milan, Italy February 25. This event is a wonderful has been touted as one of the most effective chief executives in networking opportunity for abstract authors, modern American history. A leader to whom America and much of attendees and exhibitors. The Abstract Café the world turned to in a time of crisis, Giuliani was named TIME will be the sole activity of the meeting from magazine’s 2001 Person of the Year, given an honorary knighthood 8:00 – 9:00 AM in the CRT 2013 Exhibit by the Queen of England and awarded the Ronald Reagan Hall. Complimentary food and beverages will Presidential Freedom Award. Never one to shy away from a battle, be served. Giuliani almost single-handedly took on organized and white-collar crime in New York. Since leaving office, Rudy Giuliani established Giuliani Partners, a professional services firm focusing on strategic consulting, emergency preparedness and leadership.  He is also a partner in the law firm Bracewell & Giuliani.
  11. 11. REGISTRATION & HOTEL INFORMATIONREGISTRATION THE OMNI SHOREHAM HOTELPlease register early. Advance registrations will not be accepted after February 20, 2013. After this date, registration will only be 2500 Calvert Street NWavailable on-site for an additional fee of $100. Registrations will not be accepted by telephone. For more information, call (202) 877- Washington, DC 200088206 or email Phone: (202) 234-0700 SCIENTIST / RESERVE YOUR ROOM ALLIED HEALTH INDUSTRY REGULATORY AGENCY A block of rooms has been reserved at the REGISTRATION TYPE PHYSICIAN FELLOW RESEARCH PROFESSIONAL PROFESSIONAL EMPLOYEEu discounted rate of $259 per room, per PROFESSIONAL night, single or double occupancy for CRT $840 - 2013 attendees. The tax is 14.5% per FULL MEETING $590* $590 $590 $1190 $350 $990* room, per night. SUNDAY ONLY $575 $195 There are two ways to reserve your room: MONDAY ONLY $295 BY PHONE: Please call Central Reservations at: 1-800-THE-OMNIu Proof of government regulatory agency status is required for special discount (US FDA or NIH only). (800-843-6664). Please indicate that you*Specified full meeting registrants will receive a complimentary one-year subscription to CRM Journal. will be attending “CRT 2013” to receive the preferred group rate.EARLY REGISTRATION DISCOUNT FOR PHYSICIANS ONLINE: Visit andThe earlier you register, the lower the registration fee. click on the ‘Hotel Information’ link listed on the left side for a direct link to make REGISTRATION DATE Now – October 31, 2012 November 1, 2012 – February 20, 2013 online hotel reservations. The cut-off date for making reservations FEE $840 $990 is Friday, January 25, 2013. Reservation requests received after that date willCANCELLATION POLICY be based on availability at the hotel’sCancellations made in writing before November 1, 2012 will be refunded in full. Cancellations made in writing between November prevailing rates.1, 2012 and December 31, 2012 will be subject to a $150 cancellation fee. No refunds will be given after December 31, 2012.Cancellations will not be accepted by telephone. In the unlikely event that the course is canceled, MedStar Washington HospitalCenter will refund the registration fee, but is not responsible for any travel costs. FOR THE MOST UPDATED PROGRAM INFORMATION PLEASE VISIT CRTMEETING.ORG
  12. 12. CRT 2013 NON-PROFIT ORG. 110 Irving Street, NW, Suite 6D21 U.S. POSTAGE Washington, DC 20010 PAID WASHINGTON HOSPITAL CENTERHIGHLIGHTS FOR CRT 2013› 300 Renowned Faculty› 7 Live Case Sites from Around the World› Simulators and Hands-On Workshops› Expanded Valve and Structural Heart Revolution Program› Updated Atherosclerosis, Plaque Imaging and Lipid Therapy Course› Bioabsorbable Scaffold and DCB Technologies Symposia› New Renal Denervation for Resistant Hypertension Course› iMPACT Trials› Abstracts to be published in JACC Interventions› FDA Town Hall MeetingIMPORTANT DEADLINESCALL FOR SUBMISSION DEADLINEAbstracts November 16, 2012Cardiovascular Innovations November 16, 2012Interesting Cases November 16, 2012Young Leaders November 16, 2012iMPACT Trials December 20, 2012 Questions? Please call 202-877-8206 or email